{"id":"afatinib-treatment","safety":{"commonSideEffects":[{"rate":"46%","effect":"Diarrhea"},{"rate":"45%","effect":"Rash"},{"rate":"38%","effect":"Nausea"},{"rate":"35%","effect":"Vomiting"},{"rate":"34%","effect":"Fatigue"},{"rate":"32%","effect":"Dyspnea"},{"rate":"29%","effect":"Cough"},{"rate":"28%","effect":"Headache"},{"rate":"26%","effect":"Anorexia"},{"rate":"25%","effect":"Weight loss"}]},"_chembl":{"chemblId":"CHEMBL2105712","moleculeType":"Small molecule","molecularWeight":"718.09"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Afatinib is a potent and irreversible inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, which is involved in the signaling pathways that promote the growth and survival of cancer cells.","oneSentence":"Epidermal growth factor receptor (EGFR) inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:20:05.803Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT06385483","phase":"PHASE2","title":"Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-02-28","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma","enrollment":19},{"nctId":"NCT02465060","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-17","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma","enrollment":6452},{"nctId":"NCT01783587","phase":"PHASE1","title":"Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2013-02","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":29},{"nctId":"NCT07185997","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations","status":"RECRUITING","sponsor":"ArriVent BioPharma, Inc.","startDate":"2025-12-17","conditions":"Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer","enrollment":480},{"nctId":"NCT05364073","phase":"PHASE1","title":"Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"ArriVent BioPharma, Inc.","startDate":"2022-06-30","conditions":"Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer","enrollment":160},{"nctId":"NCT02438722","phase":"PHASE2, PHASE3","title":"S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2015-05-07","conditions":"Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer","enrollment":174},{"nctId":"NCT02979977","phase":"PHASE2","title":"Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck","status":"COMPLETED","sponsor":"Yale University","startDate":"2017-03-24","conditions":"Squamous Cell Cancers of the Head and Neck","enrollment":50},{"nctId":"NCT05070403","phase":"PHASE2","title":"Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-10-01","conditions":"Squamous Cell Carcinoma","enrollment":25},{"nctId":"NCT06302621","phase":"PHASE1","title":"Pemigatinib + Afatinib in Advanced Refractory Solid Tumors","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-04-17","conditions":"Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor","enrollment":70},{"nctId":"NCT01856478","phase":"PHASE3","title":"LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-06-07","conditions":"Head and Neck Neoplasms","enrollment":340},{"nctId":"NCT06494189","phase":"PHASE1","title":"Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma","status":"COMPLETED","sponsor":"West China Hospital","startDate":"2024-07-31","conditions":"Head and Neck Cancer","enrollment":9},{"nctId":"NCT07040956","phase":"PHASE2","title":"A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2025-06-28","conditions":"Head and Neck Squamous Cell Carcinoma, Low-dose Radiotherapy, Immunotherapy","enrollment":98},{"nctId":"NCT07271446","phase":"PHASE1","title":"An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer","status":"COMPLETED","sponsor":"Precision Biotech Taiwan Corp.","startDate":"2018-09-01","conditions":"Non-small Cell Lung Cancer","enrollment":8},{"nctId":"NCT07267247","phase":"","title":"Cancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Taichung Veterans General Hospital","startDate":"2022-06-01","conditions":"Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung), Drug-Related Side Effects and Adverse Reactions (MeSH Term), Egfr Tyrosine Kinase Inhibitor","enrollment":100},{"nctId":"NCT06753747","phase":"PHASE1, PHASE2","title":"A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2025-09-10","conditions":"Esophagus Cancer","enrollment":45},{"nctId":"NCT06804850","phase":"PHASE2","title":"Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC","status":"WITHDRAWN","sponsor":"West China Hospital","startDate":"2025-01-20","conditions":"Head and Neck Cancer","enrollment":""},{"nctId":"NCT06897735","phase":"PHASE1","title":"Exploratory Study of Inhaled Afatinib Dimaleate PK Profile","status":"NOT_YET_RECRUITING","sponsor":"Petrov, Andrey","startDate":"2025-11-09","conditions":"Lung Cancer, Oral Cancer, Melanoma","enrollment":24},{"nctId":"NCT04185883","phase":"PHASE1","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2019-12-17","conditions":"Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation","enrollment":610},{"nctId":"NCT03785249","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mirati Therapeutics Inc.","startDate":"2019-01-15","conditions":"Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease","enrollment":731},{"nctId":"NCT04439136","phase":"PHASE2","title":"Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-12","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":40},{"nctId":"NCT05517330","phase":"PHASE2","title":"Neoadjuvant Tislelizumab With Afatinib for Resectable Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"West China Hospital","startDate":"2022-09-19","conditions":"Head and Neck Cancer","enrollment":23},{"nctId":"NCT06709859","phase":"PHASE2","title":"Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC","status":"RECRUITING","sponsor":"Shandong Public Health Clinical Center","startDate":"2025-05-01","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT02191891","phase":"PHASE1","title":"Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-10-21","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":32},{"nctId":"NCT07036016","phase":"","title":"Interstitial Pneumonitis Associated With EGFR-TKI and Combined With PD-1/PD-L1","status":"COMPLETED","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2015-01-01","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":67818},{"nctId":"NCT07010120","phase":"PHASE1, PHASE2","title":"A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2025-06-10","conditions":"HNSCC, Lysogenic HSV Virus, Neoadjuvant Therapy","enrollment":29},{"nctId":"NCT05516589","phase":"PHASE2","title":"Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC","status":"COMPLETED","sponsor":"West China Hospital","startDate":"2022-09-12","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":40},{"nctId":"NCT01880515","phase":"PHASE2","title":"Tetracycline as a Prophylaxis for Rash in Patients With NSCLC Receiving Treatment With BIBW2992 (Afatinib)","status":"COMPLETED","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2010-12","conditions":"Skin Rash, Lung Cancer","enrollment":107},{"nctId":"NCT05432518","phase":"EARLY_PHASE1","title":"Pilot Trial for Treatment of Recurrent Glioblastoma","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2023-06-27","conditions":"Glioblastoma, Recurrent Disease, Recurrent Glioblastoma","enrollment":10},{"nctId":"NCT02122172","phase":"PHASE2","title":"Afatinib in Advanced Refractory Urothelial Cancer","status":"TERMINATED","sponsor":"University of Chicago","startDate":"2017-09-13","conditions":"Distal Urethral Cancer, Proximal Urethral Cancer, Recurrent Bladder Cancer","enrollment":32},{"nctId":"NCT01853826","phase":"PHASE3","title":"An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-07-17","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":481},{"nctId":"NCT05834348","phase":"","title":"A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-06-23","conditions":"Non-Small Cell Lung Cancer","enrollment":5279},{"nctId":"NCT05298176","phase":"PHASE2","title":"Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2022-01-04","conditions":"Non-Small Cell Lung Cancer","enrollment":5},{"nctId":"NCT04206787","phase":"","title":"The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2020-05-20","conditions":"Non-squamous, Non-Small Cell Lung Cancer","enrollment":72},{"nctId":"NCT02424617","phase":"PHASE1, PHASE2","title":"A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"BerGenBio ASA","startDate":"2015-04-19","conditions":"Non-Small Cell Lung Cancer","enrollment":40},{"nctId":"NCT05215548","phase":"PHASE2","title":"Primary Tumor Resection With EGFR TKI for Stage IV NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2021-09-27","conditions":"NSCLC Stage IV","enrollment":100},{"nctId":"NCT02597946","phase":"PHASE2","title":"Afatinib in NSCLC With HER2 Mutation","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-03-18","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":18},{"nctId":"NCT03083678","phase":"PHASE2","title":"Afatinib in Locally Advanced and Metastatic Chordoma","status":"COMPLETED","sponsor":"Leiden University Medical Center","startDate":"2018-06-21","conditions":"Chordoma","enrollment":43},{"nctId":"NCT01214616","phase":"PHASE1","title":"BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-10-01","conditions":"Neoplasms","enrollment":17},{"nctId":"NCT02171650","phase":"PHASE1","title":"BIBW 2992 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2004-12-01","conditions":"Neoplasms","enrollment":7},{"nctId":"NCT06759857","phase":"PHASE3","title":"FHND9041 Versus Afatinib for Non-small Cell Lung Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.","startDate":"2021-08-01","conditions":"Non Small Cell Lung Cancer","enrollment":350},{"nctId":"NCT02951091","phase":"NA","title":"Biomarker-Integrated Umbrella, Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2016-01-01","conditions":"Gastric Cancer","enrollment":400},{"nctId":"NCT04795245","phase":"","title":"Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-08-26","conditions":"Non-squamous, Non-Small Cell Lung Cancer","enrollment":805},{"nctId":"NCT06741982","phase":"PHASE1","title":"A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2024-12-15","conditions":"HNSCC, Lysogenic HSV Virus, Neoadjuvant Therapy","enrollment":21},{"nctId":"NCT06648096","phase":"PHASE1, PHASE2","title":"Afatinib in Patients with Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)","status":"RECRUITING","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2024-11-08","conditions":"Fanconi Anemia, Head and Neck Squamous Cell Carcinoma","enrollment":25},{"nctId":"NCT04183712","phase":"PHASE2","title":"Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2020-06-01","conditions":"Gallbladder Carcinoma","enrollment":102},{"nctId":"NCT04750824","phase":"","title":"Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2020-10-15","conditions":"Non-squamous, Non-Small Cell Lung Cancer","enrollment":110},{"nctId":"NCT04839471","phase":"PHASE2","title":"BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study)","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2021-08-06","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":49},{"nctId":"NCT04909073","phase":"","title":"Observational Study of Afatinib 30 mg Daily","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2022-10-25","conditions":"Non-Small Cell Lung Cancer, Epidermal Growth Factor Receptor Mutation","enrollment":69},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT01542437","phase":"PHASE2","title":"Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2012-01","conditions":"Non-Small Cell Lung Cancer, EGFR, HER-2","enrollment":66},{"nctId":"NCT02768337","phase":"PHASE1, PHASE2","title":"Cambridge Brain Mets Trial 1","status":"TERMINATED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2015-03-10","conditions":"Lung Cancer, Breast Cancer, Brain Cancer","enrollment":26},{"nctId":"NCT02925234","phase":"PHASE2","title":"The Drug Rediscovery Protocol (DRUP Trial)","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2016-08","conditions":"Cancer, Tumors, Neoplasm","enrollment":1550},{"nctId":"NCT04397432","phase":"","title":"Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Retrospective Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tian Xie","startDate":"2020-08-28","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":878},{"nctId":"NCT02795156","phase":"PHASE2","title":"Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2016-09-28","conditions":"Non-small Cell Lung Carcinoma, Urothelial Carcinoma, Gastrointestinal Carcinoma, Non-colon","enrollment":100},{"nctId":"NCT03088059","phase":"PHASE2","title":"Biomarker-based Study in R/M SCCHN","status":"UNKNOWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2017-11-16","conditions":"Carcinoma, Squamous Cell of Head and Neck","enrollment":340},{"nctId":"NCT01522768","phase":"PHASE2","title":"Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-03","conditions":"Esophageal Cancer, Gastric Cancer","enrollment":42},{"nctId":"NCT03727724","phase":"PHASE2","title":"Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2018-12-04","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":37},{"nctId":"NCT05927844","phase":"PHASE1","title":"XH-30002 Capsule Combined With Afatinib Tablets for the Treatment of Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2023-06","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":20},{"nctId":"NCT01824823","phase":"PHASE2","title":"Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence","status":"TERMINATED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2014-06-30","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":3},{"nctId":"NCT05445791","phase":"PHASE3","title":"Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations","status":"UNKNOWN","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2021-07-15","conditions":"Non Small Cell Lung Cancer","enrollment":312},{"nctId":"NCT04179890","phase":"","title":"The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-12-17","conditions":"Non-squamous, Non-Small Cell Lung Cancer","enrollment":462},{"nctId":"NCT05865132","phase":"PHASE2","title":"Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction","status":"RECRUITING","sponsor":"AIPING ZHOU","startDate":"2023-04-06","conditions":"Esophagus Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT03115567","phase":"PHASE2","title":"A Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2017-02-16","conditions":"Acneiform Rash, Papulopustular Eruption","enrollment":14},{"nctId":"NCT02805530","phase":"NA","title":"Radical Treatment of Synchronous Oligometastatic Non-Small Cell Lung Carcinoma","status":"COMPLETED","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2015-06","conditions":"Carcinoma, Non-Small-Cell Lung, Synchronous Neoplasms","enrollment":36},{"nctId":"NCT03827070","phase":"PHASE1","title":"Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung Carcinoma","status":"UNKNOWN","sponsor":"Center Trials & Treatment Europe","startDate":"2019-03-05","conditions":"Non Small Cell Lung Cancer","enrollment":12},{"nctId":"NCT05818982","phase":"PHASE2","title":"To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC","status":"UNKNOWN","sponsor":"Peking University","startDate":"2023-02-09","conditions":"Advanced Esophageal Squamous Cell Carcinoma","enrollment":72},{"nctId":"NCT05267288","phase":"PHASE2","title":"Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Qingdao Central Hospital","startDate":"2021-02-01","conditions":"PFS","enrollment":30},{"nctId":"NCT02501603","phase":"PHASE2","title":"Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2016-07","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":72},{"nctId":"NCT04201756","phase":"PHASE2","title":"Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma","status":"COMPLETED","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2020-07-26","conditions":"Lung Adenocarcinoma Stage III, EGFR Gene Mutation","enrollment":47},{"nctId":"NCT03574402","phase":"PHASE2","title":"Phase II Umbrella Study Directed by Next Generation Sequencing","status":"UNKNOWN","sponsor":"Guangdong Association of Clinical Trials","startDate":"2018-07-09","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":400},{"nctId":"NCT05519917","phase":"PHASE2","title":"Study to Evaluate the Efficacy of Afatinib in Skull Base Chordoma","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2022-10-01","conditions":"Chordoma of Clivus","enrollment":20},{"nctId":"NCT03908892","phase":"NA","title":"Effect of Zanthoxylum Nitidum Tincture for Paronychia Caused by Afatinib","status":"UNKNOWN","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2019-06-12","conditions":"Paronychia","enrollment":110},{"nctId":"NCT02716311","phase":"PHASE2","title":"Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer","status":"COMPLETED","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2016-05","conditions":"Non Small Cell Lung Cancer","enrollment":118},{"nctId":"NCT05467189","phase":"","title":"Antineoplastic Drugs in Elderly Patients","status":"RECRUITING","sponsor":"Shandong University","startDate":"2021-01-01","conditions":"Cancer","enrollment":500},{"nctId":"NCT01320280","phase":"PHASE2","title":"BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer","status":"TERMINATED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2011-05","conditions":"Refractory Cancer","enrollment":29},{"nctId":"NCT02551718","phase":"NA","title":"High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-09-11","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia","enrollment":34},{"nctId":"NCT03623750","phase":"PHASE1, PHASE2","title":"E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C","status":"COMPLETED","sponsor":"Instituto Oncológico Dr Rosell","startDate":"2018-07-06","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":23},{"nctId":"NCT02451553","phase":"PHASE1","title":"Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-11-05","conditions":"Advanced Malignant Solid Neoplasm, Bile Duct Carcinoma, Recurrent Malignant Solid Neoplasm","enrollment":41},{"nctId":"NCT02440854","phase":"","title":"Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-02-16","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":80},{"nctId":"NCT01156545","phase":"PHASE2","title":"BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC","status":"COMPLETED","sponsor":"National Cancer Center, Korea","startDate":"2010-10","conditions":"Non-small Cell Lung Cancer","enrollment":68},{"nctId":"NCT03239015","phase":"PHASE2","title":"Efficacy and Safety of Precision Therapy in Refractory Tumor","status":"UNKNOWN","sponsor":"Baodong Qin","startDate":"2017-01-01","conditions":"Rare Tumor, Refractory Tumor","enrollment":300},{"nctId":"NCT01415674","phase":"PHASE2","title":"Research of Biomarkers of Activity and Efficacy of BIBW2992 in Untreated Non-metastatic HNSCC Patients","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2012-01","conditions":"Carcinoma, Squamous Cell of Head and Neck","enrollment":61},{"nctId":"NCT05204758","phase":"PHASE3","title":"Prophylactic TCM for Mitigation of EGFR-TKI Related Dermatological Adverse Effect","status":"COMPLETED","sponsor":"China Medical University Hospital","startDate":"2016-05-12","conditions":"Advanced Lung Adenocarcinoma","enrollment":30},{"nctId":"NCT04552535","phase":"","title":"A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2020-05-08","conditions":"Squamous Non-small Cell Lung Cancer","enrollment":200},{"nctId":"NCT05164848","phase":"PHASE1","title":"JMT101 Combined With Afatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Standard Therapy","status":"UNKNOWN","sponsor":"Peking University","startDate":"2021-12-25","conditions":"Esophageal Squamous Carcinoma","enrollment":50},{"nctId":"NCT03481842","phase":"PHASE1, PHASE2","title":"Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis","status":"WITHDRAWN","sponsor":"BioGene Pharmaceutical Ltd.","startDate":"2021-10-10","conditions":"Endometriosis, Endometriosis Ovary, Endometriosis Externa","enrollment":""},{"nctId":"NCT01288430","phase":"PHASE1","title":"A Study of DS-2248 in Participants With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Daiichi Sankyo","startDate":"2011-03-29","conditions":"Solid Tumors, Non-small Cell Lung Carcinoma","enrollment":60},{"nctId":"NCT02736513","phase":"PHASE2","title":"Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases","status":"UNKNOWN","sponsor":"Soroka University Medical Center","startDate":"2016-05","conditions":"Lung Cancer","enrollment":40},{"nctId":"NCT02629523","phase":"PHASE2","title":"Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA","status":"COMPLETED","sponsor":"Chonnam National University Hospital","startDate":"2016-06-01","conditions":"Lung Neoplasms, EGFR Gene Mutation","enrollment":21},{"nctId":"NCT04880811","phase":"PHASE2","title":"Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification","status":"UNKNOWN","sponsor":"Peking University","startDate":"2021-07","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":43},{"nctId":"NCT04930133","phase":"","title":"Retrospective Multi-cohort Study of Frontline Afatinib Followed by 2nd Line Therapy Including Osimertinib, Chemotherapy or Other Therapy","status":"UNKNOWN","sponsor":"Seoul St. Mary's Hospital","startDate":"2020-02-24","conditions":"NSCLC","enrollment":737},{"nctId":"NCT01427478","phase":"PHASE3","title":"Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"Centre Leon Berard","startDate":"2011-09","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":134},{"nctId":"NCT04814056","phase":"PHASE4","title":"To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion","status":"UNKNOWN","sponsor":"Shanghai Chest Hospital","startDate":"2021-06-01","conditions":"NRG1-fused Non-small Cell Lung Cancer","enrollment":15},{"nctId":"NCT02747953","phase":"PHASE2","title":"Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2011-07","conditions":"Non-small Cell Lung Cancer","enrollment":50},{"nctId":"NCT04448379","phase":"PHASE1","title":"Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2020-06-29","conditions":"Locally Advanced or Metastatic Non-Small Cell Lung Cancer","enrollment":48},{"nctId":"NCT03370770","phase":"","title":"Afatinib Osimertinib Sequencing NIS","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-12-28","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":204},{"nctId":"NCT04640870","phase":"","title":"The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib","status":"COMPLETED","sponsor":"Hellenic Cooperative Oncology Group","startDate":"2015-03-15","conditions":"Non Small Cell Lung Cancer, EGF-R Positive Non-Small Cell Lung Cancer, EGFR Gene Mutation","enrollment":59},{"nctId":"NCT01999985","phase":"PHASE1","title":"Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2013-12-31","conditions":"Lung Cancer, Non-small Cell Lung Cancer (NSCLC)","enrollment":25},{"nctId":"NCT02762877","phase":"","title":"Concordance of Key Actionable Genomic Alterations as Assessed in Tumor Tissue and Plasma in Non Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Genomic Health®, Inc.","startDate":"2016-04","conditions":"Non Small Cell Lung Carcinoma","enrollment":140},{"nctId":"NCT04533321","phase":"PHASE2","title":"A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2020-09","conditions":"Squamous Cell Carcinoma","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":196,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Afatinib treatment","genericName":"Afatinib treatment","companyName":"Sheba Medical Center","companyId":"sheba-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Epidermal growth factor receptor (EGFR) inhibitor Used for Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}